Total Payments
$653,703
2024 Payments
$44,267
Companies
24
Transactions
463
Medicare Patients
12,547
Medicare Billing
$150,132
Payment Breakdown by Category
Consulting$403,650 (61.7%)
Research$146,917 (22.5%)
Travel$58,190 (8.9%)
Other$37,723 (5.8%)
Food & Beverage$7,122 (1.1%)
Education$101.45 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $403,650 | 147 | 61.7% |
| Unspecified | $146,917 | 55 | 22.5% |
| Travel and Lodging | $58,190 | 109 | 8.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $36,723 | 13 | 5.6% |
| Food and Beverage | $7,122 | 135 | 1.1% |
| Honoraria | $1,000 | 1 | 0.2% |
| Education | $101.45 | 3 | 0.0% |
Payments by Type
General
$506,787
408 transactions
Research
$146,917
55 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $177,622 | 22 | $0 (2024) |
| GlaxoSmithKline, LLC. | $171,015 | 111 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $82,012 | 93 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $36,018 | 31 | $0 (2024) |
| AstraZeneca UK Limited | $33,066 | 23 | $0 (2024) |
| Merck Sharp & Dohme LLC | $28,927 | 31 | $0 (2024) |
| Galderma Research & Development, LLC | $19,275 | 24 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $17,181 | 20 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $14,950 | 4 | $0 (2024) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $13,120 | 5 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $44,267 | 25 | ABBVIE INC. ($24,500) |
| 2023 | $156,102 | 37 | AbbVie Inc. ($116,547) |
| 2022 | $22,475 | 11 | AstraZeneca Pharmaceuticals LP ($7,800) |
| 2021 | $26,184 | 19 | AstraZeneca Pharmaceuticals LP ($6,000) |
| 2020 | $95,693 | 40 | GlaxoSmithKline, LLC. ($52,481) |
| 2019 | $89,885 | 123 | GlaxoSmithKline, LLC. ($21,915) |
| 2018 | $134,157 | 109 | GlaxoSmithKline, LLC. ($85,703) |
| 2017 | $84,940 | 99 | AstraZeneca Pharmaceuticals LP ($21,070) |
All Payment Transactions
463 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $5,250.00 | General |
| 11/25/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| 10/17/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,450.00 | General |
| 10/16/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $6,300.00 | General |
| Category: IMMUNOLOGY | ||||||
| 09/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | STIOLTO RESPIMAT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,417.44 | General |
| Category: RESPIRATORY | ||||||
| 09/23/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 09/02/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Respiratory | ||||||
| 08/08/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis | ||||||
| 08/08/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $500.00 | Research |
| Study: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis | ||||||
| 07/24/2024 | Pulmonx Corporation | ZEPHYR ENDOBRONCHIAL VALVE (Device) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: PULMONOLOGY | ||||||
| 07/24/2024 | Pulmonx Corporation | ZEPHYR ENDOBRONCHIAL VALVE (Device) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: PULMONOLOGY | ||||||
| 05/30/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 05/09/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects with Chronic Kidney Disease with Associated Moderate to Severe Pruritus | ||||||
| 05/09/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $500.00 | Research |
| Study: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis | ||||||
| 04/26/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 04/11/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $750.00 | Research |
| Study: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis | ||||||
| 04/11/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $750.00 | Research |
| Study: A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis | ||||||
| 03/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 03/14/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $250.00 | Research |
| Study: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis | ||||||
| 01/29/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis | ||||||
| 01/17/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 01/09/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| 01/04/2024 | Galderma Laboratories, L.P. | — | — | Cash or cash equivalent | $500.00 | Research |
| Study: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Validation of Anterior Midface volume deficit scale | AbbVie Inc. | $110,597 | 2 |
| A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis | Galderma Research & Development, LLC | $12,325 | 9 |
| A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis | Galderma Research & Development, LLC | $5,200 | 10 |
| A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis | Galderma Laboratories, L.P. | $3,500 | 6 |
| Inhaled Nitric Oxide Delivered via LungFit PRO for the Treatment of Viral Community-Acquired Pneumonia in Hospitalized Adults | Beyond Air, Inc. | $2,000 | 1 |
| A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis | Galderma Laboratories, L.P. | $1,750 | 2 |
| M15-998 | AbbVie, Inc. | $1,750 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis | Galderma Research & Development, LLC | $1,000 | 4 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi | SANOFI US SERVICES INC. | $917.61 | 13 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis | Galderma Research & Development, LLC | $750.00 | 1 |
| A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects with Chronic Kidney Disease with Associated Moderate to Severe Pruritus | Galderma Laboratories, L.P. | $600.00 | 1 |
| A randomized, double blind, Sponsor open, placebo controlled, 52 week study evaluating the effect of danirixin GSK1325756 on lung function and health related quality of life in participants with mild to moderate Chronic Obstructive Pulmonary Disease CO | GlaxoSmithKline, LLC. | $401.55 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 3,659 | 4,143 | $280,791 | $47,191 |
| 2022 | 8 | 3,408 | 3,827 | $228,488 | $42,002 |
| 2021 | 7 | 3,346 | 3,744 | $210,668 | $36,101 |
| 2020 | 9 | 2,134 | 2,328 | $143,643 | $24,838 |
Total Patients
12,547
Total Services
14,042
Medicare Billing
$150,132
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2023 | 929 | 1,046 | $44,430 | $9,512 | 21.4% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 1,000 | 1,151 | $32,146 | $7,826 | 24.3% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 865 | 1,044 | $88,740 | $6,531 | 7.4% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 123 | 127 | $18,801 | $5,609 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 40 | 58 | $12,730 | $4,627 | 36.3% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 75 | 76 | $11,534 | $3,092 | 26.8% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 339 | 344 | $43,000 | $2,698 | 6.3% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 114 | 120 | $10,902 | $2,526 | 23.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 18 | 21 | $6,582 | $2,469 | 37.5% |
| 94618 | Test for exercise-induced lung stress | Facility | 2023 | 69 | 69 | $6,417 | $1,094 | 17.1% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 21 | 21 | $2,709 | $607.14 | 22.4% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 66 | 66 | $2,800 | $599.18 | 21.4% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2022 | 903 | 1,006 | $35,210 | $9,471 | 26.9% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2022 | 993 | 1,127 | $24,794 | $7,967 | 32.1% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2022 | 869 | 1,019 | $86,615 | $6,587 | 7.6% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 66 | 67 | $9,045 | $3,478 | 38.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 32 | 41 | $8,610 | $3,352 | 38.9% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 49 | 50 | $6,750 | $2,410 | 35.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2022 | 277 | 290 | $36,250 | $2,387 | 6.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 11 | 14 | $4,158 | $1,741 | 41.9% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 63 | 64 | $5,440 | $1,510 | 27.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 17 | 21 | $4,410 | $1,487 | 33.7% |
| 94618 | Test for exercise-induced lung stress | Facility | 2022 | 47 | 47 | $4,371 | $840.90 | 19.2% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2022 | 81 | 81 | $2,835 | $771.22 | 27.2% |
| 94727 | Determination of lung volumes using gas dilution or washout | Facility | 2021 | 913 | 1,018 | $35,630 | $10,243 | 28.7% |
About Dr. Robert Wise, M.D
Dr. Robert Wise, M.D is a Pulmonary Disease healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003843657.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Wise, M.D has received a total of $653,703 in payments from pharmaceutical and medical device companies, with $44,267 received in 2024. These payments were reported across 463 transactions from 24 companies. The most common payment nature is "Consulting Fee" ($403,650).
As a Medicare-enrolled provider, Wise has provided services to 12,547 Medicare beneficiaries, totaling 14,042 services with total Medicare billing of $150,132. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Baltimore, MD
- Active Since 06/27/2006
- Last Updated 05/27/2021
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1003843657
Products in Payments
- FASENRA (Drug) $34,423
- FASENRA (Biological) $19,300
- SKYRIZI (Biological) $18,725
- DUPIXENT DUPILUMAB INJECTION (Biological) $17,181
- STIOLTO RESPIMAT (Drug) $13,981
- SPIRIVA (Drug) $11,816
- MK-7264 (Drug) $10,474
- OFEV (Drug) $9,207
- DULERA (Drug) $8,268
- STIOLTO (Drug) $7,489
- Wixela Inhub (Drug) $6,099
- Yupelri (Drug) $5,281
- ZEPHYR ENDOBRONCHIAL VALVE (Device) $5,000
- SHINGRIX (Biological) $4,550
- TUDORZA PRESSAIR (Drug) $4,542
- XOLAIR (Biological) $3,434
- Pulmonx Endobronchial Valve EBV (Device) $3,274
- AIRSUPRA (Drug) $2,400
- LungFit PRO (Device) $2,000
- Spiration Valve System (Device) $1,970
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Baltimore
Alan Schwartz, M.d, M.D
Pulmonary Disease — Payments: $1.2M
Pulmonary Disease $1.2M
Hitesh Batra, Md, MD
Pulmonary Disease — Payments: $504,969
Pulmonary Disease $504,969
Hans Lee, Md, MD
Pulmonary Disease — Payments: $421,517
Pulmonary Disease $421,517
Ko-Pen Wang
Pulmonary Disease — Payments: $416,486
Pulmonary Disease $416,486
Christian Merlo, M.d, M.D
Pulmonary Disease — Payments: $183,983
Pulmonary Disease $183,983
Sonye Danoff, M.d, M.D
Pulmonary Disease — Payments: $145,641
Pulmonary Disease $145,641